Ocular Hypertension - Pipeline Review, H2 2015

Date: September 16, 2015
Pages: 116
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OEDACF7AD97EN
Leaflet:

Download PDF Leaflet

Ocular Hypertension - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Ocular Hypertension - Pipeline Review, H2 2015’, provides an overview of the Ocular Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ocular Hypertension and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ocular Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Ocular Hypertension Overview
Therapeutics Development
Pipeline Products for Ocular Hypertension - Overview
Pipeline Products for Ocular Hypertension - Comparative Analysis
Ocular Hypertension - Therapeutics under Development by Companies
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes
Ocular Hypertension - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ocular Hypertension - Products under Development by Companies
Ocular Hypertension - Products under Investigation by Universities/Institutes
Ocular Hypertension - Companies Involved in Therapeutics Development
Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Asahi Kasei Pharma Corp.
Bausch & Lomb Incorporated
Can-Fite BioPharma Ltd.
F. Hoffmann-La Roche Ltd.
Inotek Pharmaceuticals Corporation
Merck & Co., Inc.
NicOx S.A.
Ocular Therapeutix, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sylentis S.A.
Ocular Hypertension - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bimatoprost + brimonidine tartrate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(carteolol hydrochloride + latanoprost) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(dorzolamide hydrochloride + latanoprost) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(latanoprost + trabodenoson) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tafluprost + timolol maleate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMA-0076 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AR-13324 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATS-8535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bamosiran - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bimatoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DE-117 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
latanoprostene bunod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lomerizine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX-470 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCX-667 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONO-9054 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPA-6566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
piclidenoson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5093151 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-366234 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-1656 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trabodenoson - Drug Profile
Product Description
Mechanism of Action
R&D Progress
travoprost SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Hypertension - Recent Pipeline Updates
Ocular Hypertension - Dormant Projects
Ocular Hypertension - Discontinued Products
Ocular Hypertension - Product Development Milestones
Featured News & Press Releases
Jul 24, 2015: NICOX: Bausch + Lomb confirms submission of Vesneo NDA to US FDA
Jul 10, 2015: SANTEN Launches TAPTIQOM Preservative-Free Fixed Combination Eye Drops in the UK
Jun 15, 2015: Aerie Pharmaceuticals Receives Positive Feedback from FDA
May 11, 2015: Promising preclinical data on NCX 470 for glaucoma presented at ARVO by Nicox
May 11, 2015: Promising preclinical data on NCX 667 for glaucoma presented at ARVO by Nicox
Apr 23, 2015: Aerie Pharmaceuticals Reports Initial Rhopressa Phase 3 Efficacy Results
Mar 24, 2015: Aerie Pharmaceuticals Completes Enrollment in Second Phase 3 Registration Trial of Rhopressa, Novel Triple-Action Product to Lower Intraocular Pressure in Patients with Glaucoma
Feb 17, 2015: Aerie Pharmaceuticals Announces Rhopressa Presentation at 2015 Meeting of the Association for Ocular Pharmacology and Therapeutics
Jan 12, 2015: Aerie Pharmaceuticals Announces Acceleration of Expected Timeline for Reporting Efficacy Results from Phase 3 Registration Trial ('Rocket 1') of Rhopressa
Nov 25, 2014: Santen Launches TAPCOM Combination Ophthalmic Solution For The Treatment Of Glaucoma And Ocular Hypertension
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ocular Hypertension, H2 2015
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2015
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2015
Ocular Hypertension - Pipeline by Allergan Plc, H2 2015
Ocular Hypertension - Pipeline by Amakem NV, H2 2015
Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2015
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2015
Ocular Hypertension - Pipeline by Merck & Co., Inc., H2 2015
Ocular Hypertension - Pipeline by NicOx S.A., H2 2015
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2015
Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Ocular Hypertension - Pipeline by Sanofi, H2 2015
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015
Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2015
Ocular Hypertension - Pipeline by Sylentis S.A., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Ocular Hypertension Therapeutics - Recent Pipeline Updates, H2 2015
Ocular Hypertension - Dormant Projects, H2 2015
Ocular Hypertension - Dormant Projects (Contd.1), H2 2015
Ocular Hypertension - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Ocular Hypertension, H2 2015
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Asahi Kasei Pharma Corp.
Bausch & Lomb Incorporated
Can-Fite BioPharma Ltd.
F. Hoffmann-La Roche Ltd.
Inotek Pharmaceuticals Corporation
Merck & Co., Inc.
NicOx S.A.
Ocular Therapeutix, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sylentis S.A.
Skip to top


Ocular Inflammation - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 45 pages
Ocular Inflammation - Pipeline Review, Q4 2010 US$ 500.00 Nov, 2010 · 50 pages
Portal Hypertension - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 28 pages
Diabetic Hypertension - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 18 pages

Ask Your Question

Ocular Hypertension - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: